Mocetinostat for relapsed classical Hodgkin's lymphoma: An open-label, single-arm, phase 2 trial

Anas Younes, Yasuhiro Oki, R. Gregory Bociek, John Kuruvilla, Michelle Fanale, Sattva Neelapu, Amanda Copeland, Daniela Buglio, Ahmed Galal, Jeffrey Besterman, Zuomei Li, Michel Drouin, Tracy Patterson, M. Renee Ward, Jessica K. Paulus, Yuan Ji, L. Jeffrey Medeiros, Robert E. Martell

Research output: Contribution to journalArticle

134 Scopus citations

Abstract

Background: The prognosis of patients with relapsed Hodgkin's lymphoma, especially those who relapse after stem-cell transplantation, is poor, and the development of new agents for this patient population is an unmet medical need. We tested the safety and efficacy of mocetinostat, an oral isotype-selective histone deacetylase inhibitor, in patients with relapsed classical Hodgkin's lymphoma. Methods: Patients with relapsed or refractory classical Hodgkin's lymphoma aged 18 years or older were treated with mocetinostat administered orally three times per week, in 28-day cycles. Two doses were assessed (85 mg and 110 mg). Patients were treated until disease progression or prohibitive toxicity. The primary outcome was disease control rate, defined as complete response, partial response, or stable disease (for at least six cycles), analysed by intention to treat. This trial has been completed and is registered with ClinicalTrials.gov, number NCT00358982. Findings: 51 patients were enrolled. Initially, 23 patients were enrolled in the 110 mg cohort. Subsequently, because toxicity-related dose reductions were necessary in the 110 mg cohort, we treated 28 additional patients with a dose of 85 mg. On the basis of intent-to-treat analysis, the disease control rate was 35% (eight of 23 patients) in the 110 mg group and 25% (seven of 28) in the 85 mg group. 12 patients (24%) discontinued treatment because of adverse events, nine (32%) in the 85 mg cohort and three (13%) in the 110 mg cohort. The most frequent treatment-related grade 3 and 4 adverse events were neutropenia (four patients [17%] in the 110 mg group, three [11%] in the 85 mg group); fatigue (five patients [22%] in the 110 mg group, three [11%] in the 85 mg group); and pneumonia (four patients [17%] in the 110 mg group, two [7%] in the 85 mg group). Four patients, all in the 110 mg cohort, died during the study, of which two might have been related to treatment. Interpretation: Mocetinostat, 85 mg three times per week, has promising single-agent clinical activity with manageable toxicity in patients with relapsed classical Hodgkin's lymphoma. Funding: MethylGene Inc, Montreal, Canada; Celgene Corporation, Summit, NJ, USA; Tufts Medical Center, Boston, MA, USA.

Original languageEnglish (US)
Pages (from-to)1222-1228
Number of pages7
JournalThe Lancet Oncology
Volume12
Issue number13
DOIs
StatePublished - Dec 2011

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Mocetinostat for relapsed classical Hodgkin's lymphoma: An open-label, single-arm, phase 2 trial'. Together they form a unique fingerprint.

  • Cite this

    Younes, A., Oki, Y., Bociek, R. G., Kuruvilla, J., Fanale, M., Neelapu, S., Copeland, A., Buglio, D., Galal, A., Besterman, J., Li, Z., Drouin, M., Patterson, T., Ward, M. R., Paulus, J. K., Ji, Y., Medeiros, L. J., & Martell, R. E. (2011). Mocetinostat for relapsed classical Hodgkin's lymphoma: An open-label, single-arm, phase 2 trial. The Lancet Oncology, 12(13), 1222-1228. https://doi.org/10.1016/S1470-2045(11)70265-0